Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

Overview of attention for article published in Frontiers in Pharmacology, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 20 X posts from 15 X users, with an upper bound of 69,373 followers.

@reignvixen @suspendedJoey @TradeAthlete @Interikan_ @Longterms1 @DeliberationCap Mer som du kan använda för att utbilda dig då du ännu en gång är fel ute. https://t.co/8g5ykH8a01 Kort och gott, finns ett stort värde och syfte i att ansöka "Expanded Acces

4/7 This work builds on top of previous research on the value of EA data for regulators (https://t.co/560Qid5xgG), reimbursement bodies (https://t.co/46NzQBBjnL ), and in particular rare diseases (https://t.co/5SAMUD1Yba). https://t.co/5MQfnLGkWb

Generar conocimiento a partir del "uso compasivo" de medicamentos para enfermedades raras https://t.co/IJTzhPGKpB @sefh_ @EMA_News @GENESIS_SEFH @CIBERER @FProgresoysalud

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 16 additional X posts.